Predicting outcome of treatment with an anti-α4β7 integrin antibody
The invention provides methods for treating patients with anti-α4β7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-α4β7 antibody.
1. A method of treating a patient suffering from Inflammatory Bowel Disease (IBD), the method comprising
a) measuring the serum concentration of vedolizumab in a patient, wherein the patient was administered an induction phase dosing regimen of vedolizumab at least two weeks prior,
b) measuring the concentration of serum albumin in the patient,
c) measuring the body weight of the patient;
d) selecting a patient whose measurement of vedolizumab in step a) indicates low clearance, whose measurement of serum albumin in step b) is 3.8 to 5.0 g/dL, and whose body weight is <80 kg; and
e) administering vedolizumab to the selected patient, thereby treating IBD.
2. The method of claim 1 , wherein the patient is selected if the serum concentration of vedolizumab is at least 8 μg per ml.
3. The method of claim 1 , further comprising measuring an endoscopic subscore, wherein vedolizumab is continued with an endoscopic subscore of less than 3, less than 2.5, or less than 2.
4. The method of claim 1 , further comprising measuring the fecal calprotectin concentration.
5. The method of claim 1 , wherein the patient's serum albumin concentration is in the range of 4.0 to 5.0 g/dL.
6. The method of claim 1 , wherein the IBD is Crohn's Disease.
7. The method of claim 6 , further comprising measuring SES-CD, wherein vedolizumab is continued with a SES-CD score <6, and/or measuring MaRIA, wherein vedolizumab is continued with a MaRIA score <12.
8. A method of treating a patient having Crohn's disease, the method comprising
a) measuring the serum concentration of vedolizumab in a patient having Crohn's disease, measuring the concentration of serum albumin in the patient, measuring the body weight of the patient, and measuring either SES-CD or MaRIA, wherein the patient was administered an induction phase dosing regimen of vedolizumab at least two weeks prior to the measurements,
b) selecting a patient whose measurement of vedolizumab in step a) indicates low clearance, whose measurement of serum albumin in step a) is 3.5 to 5.0 g/dL, whose body weight is <80 kg; and whose SES-CD score <6 or MaRIA score <12, and
c) administering vedolizumab to the selected patient, thereby treating Crohn's disease.